W. Schroeder

发表

Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis

S. Loibl, J. Huober, A. Hasenburg, 2009, Annals of Surgical Oncology.

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau

R. Kimmig, B. Weber, S. Costa, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer.

W. Rath, S. Biesterfeld, W. Schroeder, 1997, Anticancer research.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

H. Sommer, W. Lichtenegger, J. Sehouli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).

C. Jackisch, A. du Bois, A. Burges, 2005, Gynecologic oncology.

Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up

S. Biesterfeld, C. Rudlowski, W. Schroeder, 2005, International Journal of Gynecologic Cancer.

Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up

S. Biesterfeld, C. Rudlowski, W. Schroeder, 2005, International Journal of Gynecologic Cancer.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study

P. Soergel, A. Ignatov, P. Hantschmann, 2022, Cancers.

Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group.

T. Fehm, A. Reuss, J. Sehouli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.

T. Bauknecht, C. Jackisch, S. Costa, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes

Jian-Bing Fan, E. Goode, M. Parmar, 2017, Clinical Cancer Research.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

T. Fehm, A. Reuss, S. Hauptmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study

T. Fehm, A. Reuss, S. Hauptmann, 2015, British Journal of Cancer.

Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.

A. Reuss, S. Hauptmann, C. Fotopoulou, 2012 .

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

T. Fehm, A. Reuss, S. Hauptmann, 2014 .

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

R. Kimmig, J. Blohmer, A. du Bois, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial)

T. Bauknecht, S. Costa, W. Meier, 2001 .

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial.

B. Weber, S. Loibl, C. Jackisch, 2004, Journal of Clinical Oncology.